Regorafenib plus Envafolimab for treatment-resistant gastrointestinal stromal tumors
Part of Cancer, Digestive system, Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This study tests a combination of two drugs (regorafenib and envafolimab) for gastrointestinal stromal tumors (a type of stomach/bowel cancer) that have stopped responding to standard treatments. The trial compares this combination to other doctor-selected treatments to see if it slows tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- Your tumor must be confirmed as a gastrointestinal stromal tumor by biopsy
- Your cancer has worsened or you couldn't tolerate previous treatments like imatinib, sunitinib, regorafenib, or ripretinib
- Your tumor must have a specific genetic mutation (KIT exon 17 mutation) confirmed by genetic testing
- Your blood counts, liver function, and kidney function must be healthy enough for the trial
- You must be willing to provide tissue samples for testing and sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called NB003 for people with advanced GIST (a type of stomach or intestinal tumor) that has stopped responding to or could not be tolerated after standard treatments like imatinib or sunitinib. The goal is to see if NB003 can help shrink or control the tumor.
This study tests a combination of two drugs—regorafenib (a targeted therapy) and envafolimab (an immunotherapy)—for people with advanced GIST whose tumors have a specific KIT gene mutation (exon 17) and have stopped responding to standard treatments.
This trial tests a combination of a GSL synthesis inhibitor, an immunotherapy drug, and/or regorafenib in people with a specific type of colorectal cancer (pMMR/MSS) that has not responded to at least two prior treatments. The goal is to see if this new approach can help shrink or control the cancer.
This Phase 2 trial tests whether combining rivoceranib with paclitaxel can shrink or control advanced metastatic gastrointestinal stromal tumor (GIST) after standard medicines have stopped working. It may help people whose GIST has progressed despite prior treatments like imatinib, sunitinib, and regorafenib.
This study uses a blood test (ctDNA) to look for specific tumor DNA changes, then guides treatment with sunitinib or regorafenib in people with GIST that has spread or cannot be removed by surgery. It aims to see whether this ctDNA-guided approach improves outcomes compared with standard decision-making.
This trial tests a drug called lenvatinib for people with advanced GIST that has not responded to three previous treatments. It may offer a new option if standard therapies have stopped working or caused severe side effects.
Hear when a new GIST - Gastrointestinal Stromal Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.